Clark, John A. http://orcid.org/0000-0001-6916-9195
Conway Morris, Andrew http://orcid.org/0000-0002-3211-3216
Kanaris, Constantinos http://orcid.org/0000-0002-4017-4553
Inwald, David http://orcid.org/0000-0001-9518-7821
Butt, Warwick http://orcid.org/0000-0003-3543-1014
Osowicki, Joshua http://orcid.org/0000-0002-9432-6700
Schlapbach, Luregn J. http://orcid.org/0000-0003-2281-2598
Curran, Martin D. http://orcid.org/0000-0002-1589-5850
White, Deborah http://orcid.org/0000-0002-9254-996X
Daubney, Esther http://orcid.org/0000-0003-1206-0169
Agrawal, Shruti http://orcid.org/0000-0001-8695-1314
Navapurkar, Vilas http://orcid.org/0000-0002-3610-3568
Török, M. Estée http://orcid.org/0000-0001-9098-8590
Baker, Stephen http://orcid.org/0000-0003-1308-5755
Pathan, Nazima http://orcid.org/0000-0002-9447-4252
Funding for this research was provided by:
Gates Cambridge Trust (OPP1144)
Addenbrooke's Charitable Trust, Cambridge University Hospitals (900240, 900240, 900240, 900240)
NIHR Cambridge Biomedical Research Centre
Academy of Medical Sciences
Health Foundation Clinical Scientist Fellowship
Wellcome Trust (215515, WT 2005214/Z/16/Z)
MRC Clinician Scientist Fellowship (MR/V006118/1)
Action Medical Research (GN2751, GN2903, GN2751, GN2903, GN2751, GN2903)
Article History
Received: 1 February 2023
Accepted: 9 June 2023
First Online: 7 July 2023
Declarations
:
: Research was conducted in concordance with the Declaration of Helsinki. Ethical approval for the survey was obtained from the Cambridge Psychology Research Ethics Committee (PRE.2021.077) on 9 September 2021. To maintain anonymity, participants were not requested personally identifying information. Participants were asked to provide the name of their hospital, which was anonymised by the research team. On opening the survey link, participants were presented with a study information sheet. Provision of consent to participate in the project was assumed based on participants’ continuation in completing the survey instrument.Ethical approval for study interviews was granted by the Yorkshire and Humber-Bradford Leeds Research Ethics Committee (REC ref 20/YH/0089 on 26 March 2020). The interviews were a component of the Rapid Assay for Sick Children with Acute Lung infection Study, sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. Participant information sheets and consent forms are included in the InternalRef removed.
: MDC is the inventor of a patent held by the Secretary of State for Health (UK government) EP2788503, which covers some of the genetic sequences used in this study. VN is a founder, director and shareholder in Cambridge Infection Diagnostics (CID), which is a commercial company aimed at developing molecular diagnostics in infection and antimicrobial and AMR stewardship. ACM and SB are members of the Scientific Advisory Board of CID. ACM receives speaking fees from Boston Scientific. NP has received speaker fees from BioMérieux (Marcy-l’Étoile, France). All other authors declare no conflict of interest.